Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study - Marrero, Jorge A.; Kudo, Masatoshi; Venook, Alan P.; Ye, Sheng-Long; Bronowicki, Jean-Pierre; Chen, Xiao-Ping; Dagher, Lucy; Furuse, Junji; Geschwind, Jean-Francois H.; de Guevara, Laura Ladrón; Papandreou, Christos; Takayama, Tadatoshi; et al. (Journal of hepatology, 2016)
Keywords: Antineoplastic Agents; Carcinoma, Hepatocellular; Child; Child-Pugh; Clinical medicine; Drug therapy; Gastroenterology and Hepatology; GIDEON; HCC; Hepatocellular carcinoma; Humans; Liver cancer; Liver diseases; Liver Neoplasms; Medical treatment; Nexavar; Niacinamide - analogs & derivatives; Niacinamide - therapeutic use; Patient handling; Patients; Phenylurea Compounds - therapeutic use; Prospective Studies; Registries; Safety; Sorafenib; ECOG PS; Child-Pugh; TNM; AE; CI; Sorafenib; BCLC; HCC; Hepatocellular carcinoma; INR; GIDEON; Nexavar; sorafenib; adverse event; international normalized ratio; Eastern Cooperative Oncology Group performance status; Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib; tumor node metastasis; confidence interval; Barcelona Clinic Liver Cancer; hepatocellular carcinoma